Kantonsspital St.Gallen
anmelden

Skippain

Carina Hutz, Silvia Forrer, Mira Bartz Batliner & Andrea Rubbert Roth

Kurzfassung SKIPPAIN (Speed of onset of SecuKinumab-Induced relief
from Pain in Patients with AxIal SpoNdyloarthritis)
A 24-week, randomized, double-blind, placebo-controlled,
multicenter study to evaluate the efficacy and safety of
secukinumab in controlling spinal pain in patients with
axial spondyloarthritis
   
Art des Forschungsprojektes Klinische Forschung
Status Abgeschlossen
Projektstart 2018
Projektende 2019
Studiendesign This is a 24-week, randomized, double-blind, placebo-controlled, multicenter study to
evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with
axSpA. The study will consist of 2 treatment periods: a double-blind, placebo-controlled
period from Baseline to Week 8 (i.e. Treatment Period 1) and a double-blind secukinumab
treatment period from Week 8 to Week 24 (i.e. Treatment Period 2). At Baseline, patients will
be randomized to either secukinumab 150 mg or placebo. At Week 8, patients will be
re-randomized to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab
300 mg.
Verantwortliche Person / Hauptpr├╝farzt am KSSG Prof. Dr. Rubbert-Roth